BCL2L11 and ovarian cancer: We also evaluated the power of BIM as a predictive biomarker of response to GNE-493 and ABT-737 combination treatment in an independent set of seven established ovarian cancer cell lines exhibiting diverse BIM protein levels (Supplementary Fig. 7E).